

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 November 2020 (12.11.2020)



(10) International Publication Number
WO 2020/227549 A1

(51) International Patent Classification:

A61P 5/14 (2006.01) C07D 403/14 (2006.01)
C07D 401/14 (2006.01) A61K 31/53 (2006.01)
C07D 403/12 (2006.01)

(21) International Application Number:

PCT/US2020/031904

(22) International Filing Date:

07 May 2020 (07.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/845,252	08 May 2019 (08.05.2019)	US
62/944,052	05 December 2019 (05.12.2019)	US
63/005,661	06 April 2020 (06.04.2020)	US

(71) Applicant: **ALIGOS THERAPEUTICS, INC.** [US/US];
1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **VANDYCK, Koen**; Deurnestraat 74, 3583 Beringen (BE). **RABOISSON, Pierre, Jean-Marie, Bernard**; c/o Aligos Therapeutics, Inc., Bio-Incubator Leuven NV, Gaston Greenslaan, 3001 Leuven (Heverlee) (BE). **MCGOWAN, David**; Av de Biolley 80, 1150 Brussels

(BE). **DEVAL, Jerome**; 1131 Columbus Street, El Granada, California 94018 (US).

(74) Agent: **SCHORR, Kristel** et al.; Foley & Lardner LLP, 3000 K Street N. W., Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MODULATORS OF THR- β AND METHODS OF USE THEREOF





FIG. 1

(I) TL-L₂-CE-HD



(57) Abstract: Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

WO 2020/227549 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*